Quazepam

Benzodiazepine — NERVOUS SYSTEM

Key facts

Quazepam is an ofp drug in the Benzodiazepine class catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 3 molecular targets, including GABRA1|GABRB1|GABRG2, GABRB1|GABRG2|GABRA2 and GABRB1|GABRG2|GABRA3. Recorded indications include Insomnia.

• Approval status: ofp (first approved 1985 by the FDA).
• Drug class: Benzodiazepine.
• Molecular targets: GABRA1|GABRB1|GABRG2, GABRB1|GABRG2|GABRA2 and GABRB1|GABRG2|GABRA3 (3 listed in DrugCentral).
• Indications: Insomnia.
• ATC code: N05CD10 (Benzodiazepine derivatives).
• Molecular formula: C17H11ClF4N2S; molecular weight 386.79 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Insomnia

Contraindications (17)

• Alcohol intoxication
• Breastfeeding (mother)
• Coma
• Decreased respiratory function
• Depressive disorder
• Disease of liver
• Disorder of lung
• Hypoalbuminemia
• Kidney disease
• Porphyria
• Pregnancy, function
• Severe chronic obstructive pulmonary disease
• Shock
• Sleep apnea
• Sleep automatism
• Substance abuse
• Suicidal thoughts

Mechanism & targets

• Established pharmacologic class: Benzodiazepine

Molecular targets (3)

Target	Gene	Action	Activity
GABA A receptor alpha-1/beta-1/gamma-2	GABRA1|GABRB1|GABRG2	positive allosteric modulator	Ki 7.71
GABA A receptor alpha-2/beta-1/gamma-2	GABRB1|GABRG2|GABRA2	positive allosteric modulator	Ki 6.69
GABA A receptor alpha-3/beta-1/gamma-2	GABRB1|GABRG2|GABRA3	positive allosteric modulator	Ki 6.63

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-12-27	FDA	—	SCIECURE PHARMA INC

ATC classification

ATC code	Therapeutic hierarchy
N05CD10	NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Benzodiazepine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Altered state of consciousness	97.4
Suicide attempt	64.7
Intentional overdose	59.2
Blood creatine phosphokinase increased	46.6
Salivary hypersecretion	40.4
Psychiatric symptom	37.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Quazepam is on its molecule page.

• Molecular formula: C₁₇H₁₁ClF₄N₂S
• Molecular weight: 386.79 g/mol
• CAS number: 36735-22-5
• InChIKey: IKMPWMZBZSAONZ-UHFFFAOYSA-N
• PubChem CID: 4999

FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Quazepam used for?

DrugCentral lists the following indications for Quazepam: Insomnia.

How does Quazepam work?

Its molecular targets in DrugCentral include GABRA1|GABRB1|GABRG2 (positive allosteric modulator), GABRB1|GABRG2|GABRA2 (positive allosteric modulator) and GABRB1|GABRG2|GABRA3 (positive allosteric modulator).

When was Quazepam first approved?

Quazepam was first approved by the FDA in 1985.

What drug class does Quazepam belong to?

Quazepam is in the Benzodiazepine class.

What is the chemical formula of Quazepam?

Quazepam has the molecular formula C17H11ClF4N2S and a molecular weight of 386.79 g/mol.

Sources

• DrugCentral drug card 2336 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200472 — compound record and bioactivity
• PubChem CID 4999 — chemical identifiers
• DrugBank DB01589 — drug record
• FDA UNII JF8V0828ZI — substance identity
• DailyMed: FDA labels for Quazepam — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.